Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$3.25
-4.4%
$2.85
$2.12
$5.80
$337.71M1.941.55 million shs1.68 million shs
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
$2.63
+69.7%
$0.98
$0.55
$4.42
$110.91M-0.071.17 million shs20.57 million shs
CryoPort, Inc. stock logo
CYRX
CryoPort
$6.37
-6.0%
$6.20
$4.58
$9.93
$339.93M1.85532,638 shs607,870 shs
SNDL Inc. stock logo
SNDL
SNDL
$1.25
-1.6%
$1.33
$1.24
$2.40
$333.73M3.451.97 million shs1.78 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-4.41%-4.97%+43.17%+1.25%+21.27%
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
+69.68%+78.91%+200.40%+324.19%+262,999,900.00%
CryoPort, Inc. stock logo
CYRX
CryoPort
-6.05%-4.50%+3.75%+11.95%-32.95%
SNDL Inc. stock logo
SNDL
SNDL
-1.57%-3.10%-4.58%-20.89%-32.80%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
1.4319 of 5 stars
3.51.00.00.02.90.00.0
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
0.3903 of 5 stars
2.00.00.00.00.01.70.0
CryoPort, Inc. stock logo
CYRX
CryoPort
3.4309 of 5 stars
4.43.00.00.01.92.50.6
SNDL Inc. stock logo
SNDL
SNDL
3.8298 of 5 stars
3.55.00.00.03.30.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
3.00
Buy$10.14212.09% Upside
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
2.00
Hold$3.0014.07% Upside
CryoPort, Inc. stock logo
CYRX
CryoPort
2.71
Moderate Buy$11.0072.68% Upside
SNDL Inc. stock logo
SNDL
SNDL
3.00
Buy$3.63190.00% Upside

Current Analyst Ratings Breakdown

Latest CTOR, AQST, SNDL, and CYRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
6/2/2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$7.00
5/23/2025
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeHold
5/23/2025
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/15/2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
5/8/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
5/5/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $7.00
4/16/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
4/16/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
4/10/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
4/2/2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$57.56M5.61N/AN/A($0.66) per share-4.92
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
N/AN/AN/AN/A$0.64 per shareN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
$228.38M1.40N/AN/A$7.44 per share0.86
SNDL Inc. stock logo
SNDL
SNDL
$671.81M0.49N/AN/A$3.15 per share0.40
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$44.14M-$0.59N/AN/AN/A-100.02%N/A-50.31%8/5/2025 (Estimated)
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
N/AN/A0.00N/AN/A-53.88%-18.86%N/A
CryoPort, Inc. stock logo
CYRX
CryoPort
-$114.76M-$2.34N/AN/AN/A-50.15%-11.03%-5.54%8/5/2025 (Estimated)
SNDL Inc. stock logo
SNDL
SNDL
-$69.18M-$0.29N/AN/AN/A-11.48%-9.02%-7.60%7/30/2025 (Estimated)

Latest CTOR, AQST, SNDL, and CYRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q2 2025
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
-$0.09-$0.11-$0.02-$0.11$5.74 millionN/A
5/12/2025Q1 2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$0.17-$0.24-$0.07-$0.24$12.23 million$8.72 million
5/7/2025Q1 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.23-$0.22+$0.01-$0.28$56.19 million$41.04 million
5/1/2025Q1 2025
SNDL Inc. stock logo
SNDL
SNDL
-$0.06-$0.04+$0.02-$0.04$214.60 million$142.38 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
N/AN/AN/AN/AN/A
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
N/AN/AN/AN/AN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
SNDL Inc. stock logo
SNDL
SNDL
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
N/A
4.87
4.48
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
0.11
0.36
0.05
CryoPort, Inc. stock logo
CYRX
CryoPort
0.51
5.56
5.24
SNDL Inc. stock logo
SNDL
SNDL
0.10
4.62
3.12

Institutional Ownership

CompanyInstitutional Ownership
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
32.45%
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
70.52%
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
SNDL Inc. stock logo
SNDL
SNDL
N/A

Insider Ownership

CompanyInsider Ownership
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
8.35%
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
4.57%
CryoPort, Inc. stock logo
CYRX
CryoPort
10.00%
SNDL Inc. stock logo
SNDL
SNDL
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
16099.33 million91.03 millionOptionable
Citius Oncology, Inc. stock logo
CTOR
Citius Oncology
N/A71.55 million68.28 millionN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
1,18650.14 million45.12 millionOptionable
SNDL Inc. stock logo
SNDL
SNDL
2,516262.78 millionN/AOptionable

Recent News About These Companies

3 Cannabis Stocks For Investors To Secure For Future Gains
1CM Receives Court Approval for Arrangement with SNDL Inc
1CM Inc. Gains Court Approval for SNDL Arrangement
Marijuana Stocks To Watch With Strong Market Potential
3 Marijuana Stocks For The Long Term Investing
These Cannabis Companies Are Repurchasing Shares
SNDL 1Q Loss Widens

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aquestive Therapeutics stock logo

Aquestive Therapeutics NASDAQ:AQST

$3.25 -0.15 (-4.41%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$3.26 +0.02 (+0.46%)
As of 06/20/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Citius Oncology stock logo

Citius Oncology NASDAQ:CTOR

$2.63 +1.08 (+69.68%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$2.22 -0.42 (-15.78%)
As of 06/20/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

CryoPort stock logo

CryoPort NASDAQ:CYRX

$6.37 -0.41 (-6.05%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$6.37 0.00 (0.00%)
As of 06/20/2025 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

SNDL stock logo

SNDL NASDAQ:SNDL

$1.25 -0.02 (-1.57%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$1.27 +0.02 (+1.60%)
As of 06/20/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.